Loading...

We've got a brand new version of Simply Wall St! Try it out

Stallergenes Greer

BST:AA6
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AA6
BST
€724M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Stallergenes Greer plc, a biopharmaceutical company, engages in the development and commercialization of allergy immunotherapy products and services for diagnosis and treatment of allergies worldwide. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
AA6 Share Price and Events
7 Day Returns
-0.5%
BST:AA6
-5.2%
DE Pharmaceuticals
-1.7%
DE Market
1 Year Returns
-
BST:AA6
-27.8%
DE Pharmaceuticals
-10.5%
DE Market
AA6 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Stallergenes Greer (AA6) -0.5% -0.4% - - - -
DE Pharmaceuticals -5.2% -6.2% -9.3% -27.8% -23.3% 4.2%
DE Market -1.7% -1.2% 5.2% -10.5% 10.7% 11.1%
1 Year Return vs Industry and Market
  • No trading data on AA6.
  • No trading data on AA6.
Price Volatility
AA6
Industry
5yr Volatility vs Market

AA6 Value

 Is Stallergenes Greer undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Stallergenes Greer to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Stallergenes Greer.

BST:AA6 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:AA6
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.7
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.697 (1 + (1- 19%) (2.59%))
0.806
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.806 * 6.65%)
5.59%

Discounted Cash Flow Calculation for BST:AA6 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Stallergenes Greer is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

BST:AA6 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 5.59%)
2019 27.10 Analyst x3 25.67
2020 27.67 Analyst x3 24.81
2021 28.09 Est @ 1.51% 23.86
2022 28.40 Est @ 1.13% 22.85
2023 28.65 Est @ 0.86% 21.82
2024 28.84 Est @ 0.67% 20.81
2025 28.99 Est @ 0.54% 19.81
2026 29.12 Est @ 0.44% 18.84
2027 29.23 Est @ 0.38% 17.91
2028 29.33 Est @ 0.33% 17.02
Present value of next 10 years cash flows €213.41
BST:AA6 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €29.33 × (1 + 0.23%) ÷ (5.59% – 0.23%)
€548.13
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €548.13 ÷ (1 + 5.59%)10
€318.13
BST:AA6 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €213.41 + €318.13
€531.54
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €531.54 / 19.73
€26.94
BST:AA6 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:AA6 represents 0.9891x of ENXTPA:STAGR
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.9891x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 26.94 x 0.9891
€26.64
Value per share (EUR) From above. €26.64
Current discount Discount to share price of €36.30
= -1 x (€36.30 - €26.64) / €26.64
-36.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Stallergenes Greer is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Stallergenes Greer's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Stallergenes Greer's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:AA6 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €0.65
ENXTPA:STAGR Share Price ** ENXTPA (2019-05-13) in EUR €36.7
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.47x
Germany Market PE Ratio Median Figure of 427 Publicly-Listed Companies 20.76x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Stallergenes Greer.

BST:AA6 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:STAGR Share Price ÷ EPS (both in EUR)

= 36.7 ÷ 0.65

56.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stallergenes Greer is overvalued based on earnings compared to the DE Pharmaceuticals industry average.
  • Stallergenes Greer is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Stallergenes Greer's expected growth come at a high price?
Raw Data
BST:AA6 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 56.76x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
35.4%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.95x
Germany Market PEG Ratio Median Figure of 277 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

BST:AA6 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 56.76x ÷ 35.4%

1.6x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stallergenes Greer is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Stallergenes Greer's assets?
Raw Data
BST:AA6 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €23.87
ENXTPA:STAGR Share Price * ENXTPA (2019-05-13) in EUR €36.7
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.27x
Germany Market PB Ratio Median Figure of 575 Publicly-Listed Companies 1.78x
BST:AA6 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:STAGR Share Price ÷ Book Value per Share (both in EUR)

= 36.7 ÷ 23.87

1.54x

* Primary Listing of Stallergenes Greer.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stallergenes Greer is good value based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Stallergenes Greer's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Stallergenes Greer has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AA6 Future Performance

 How is Stallergenes Greer expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
35.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Stallergenes Greer expected to grow at an attractive rate?
  • Stallergenes Greer's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Stallergenes Greer's earnings growth is expected to exceed the Germany market average.
  • Stallergenes Greer's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:AA6 Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:AA6 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 35.4%
BST:AA6 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 5.9%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:AA6 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:AA6 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 373 1
2022-12-31 352 1
2021-12-31 330 1
2020-12-31 308 56 27 3
2019-12-31 293 47 22 3
BST:AA6 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 277 42 13
2018-09-30 275 38 13
2018-06-30 273 34 13
2018-03-31 267 15 1
2017-12-31 260 -4 -10
2017-09-30 249 -22 -20
2017-06-30 238 -40 -30
2017-03-31 212 -59 -45
2016-12-31 186 -78 -61
2016-09-30 167 -84 -71
2016-06-30 147 -91 -81
2016-03-31 115 -65 -65

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Stallergenes Greer's earnings are expected to grow significantly at over 20% yearly.
  • Stallergenes Greer's revenue is expected to grow by 5.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:AA6 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Stallergenes Greer Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:AA6 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 1.58 1.72 1.43 2.00
2019-12-31 1.17 1.17 1.17 1.00
BST:AA6 Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 0.65
2018-09-30 0.64
2018-06-30 0.64
2018-03-31 0.07
2017-12-31 -0.50
2017-09-30 -1.02
2017-06-30 -1.54
2017-03-31 -2.31
2016-12-31 -3.07
2016-09-30 -3.94
2016-06-30 -5.01
2016-03-31 -5.38

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Stallergenes Greer is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Stallergenes Greer's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Stallergenes Greer has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AA6 Past Performance

  How has Stallergenes Greer performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Stallergenes Greer's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Stallergenes Greer has delivered over 20% year on year earnings growth in the past 5 years.
  • Stallergenes Greer has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Stallergenes Greer has become profitable in the last year making it difficult to compare the DE Pharmaceuticals industry average.
Earnings and Revenue History
Stallergenes Greer's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Stallergenes Greer Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:AA6 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 277.05 12.76 120.69 37.56
2018-09-30 275.02 12.71 122.51 37.00
2018-06-30 272.99 12.66 124.33 36.44
2018-03-31 266.61 1.39 128.05 37.83
2017-12-31 260.23 -9.87 131.77 39.22
2017-09-30 249.07 -20.13 136.86 42.94
2017-06-30 237.90 -30.38 141.96 46.67
2017-03-31 212.15 -45.45 145.08 46.04
2016-12-31 186.39 -60.52 148.20 45.40
2016-09-30 166.79 -70.59 150.00 42.38
2016-06-30 147.19 -80.66 151.81 39.37
2016-03-31 114.50 -64.97 120.34 29.50
2015-12-31 81.82 -49.28 88.88 19.63
2015-06-30 12.75 -7.69 8.47 0.72
2014-12-31 -0.05 0.05

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Stallergenes Greer has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Stallergenes Greer used its assets less efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.
  • Stallergenes Greer has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Stallergenes Greer's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Stallergenes Greer has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AA6 Health

 How is Stallergenes Greer's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Stallergenes Greer's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Stallergenes Greer is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Stallergenes Greer's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Stallergenes Greer's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 10.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Stallergenes Greer Company Filings, last reported 4 months ago.

BST:AA6 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 471.20 18.76 73.97
2018-09-30 471.20 18.76 73.97
2018-06-30 465.69 18.70 71.43
2018-03-31 465.69 18.70 71.43
2017-12-31 447.33 18.52 50.86
2017-09-30 447.33 18.52 50.86
2017-06-30 460.78 16.02 48.77
2017-03-31 460.78 16.02 48.77
2016-12-31 489.21 23.12 71.28
2016-09-30 489.21 23.12 71.28
2016-06-30 493.69 15.56 84.99
2016-03-31 493.69 15.56 84.99
2015-12-31 539.98 17.67 150.19
2015-06-30 267.54 15.06 10.26
2014-12-31 0.02 0.00 0.06
  • Stallergenes Greer's level of debt (4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Stallergenes Greer's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (222.2%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 23.4x coverage).
X
Financial health checks
We assess Stallergenes Greer's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Stallergenes Greer has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AA6 Dividends

 What is Stallergenes Greer's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Stallergenes Greer dividends. Estimated to be 0.71% next year.
If you bought €2,000 of Stallergenes Greer shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Stallergenes Greer's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Stallergenes Greer's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:AA6 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:AA6 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.23 3.00
2019-12-31 0.31 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Stallergenes Greer has not reported any payouts.
  • Unable to verify if Stallergenes Greer's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Stallergenes Greer's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Stallergenes Greer has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Stallergenes Greer's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Stallergenes Greer's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Stallergenes Greer afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Stallergenes Greer has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AA6 Management

 What is the CEO of Stallergenes Greer's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michele Antonelli
AGE 58
TENURE AS CEO 0.3 years
CEO Bio

Mr. Michele Antonelli serves as Chief Executive Officer of Stallergenes Greer plc since January 04, 2019. He has been Director of Stallergenes Greer Plc since December 12, 2018. He served as Executive Vice President, Head of Europe & Rest of World and President of Stallergenes SAS at Stallergenes Greer Plc since November 2015 until January 04, 2019. Mr. Antonelli’s primary focus is to deliver the value proposition of state-of-the-art medicines to key Allergy Immunotherapy markets. He is also play a pivotal role in helping build Stallergenes commercial organizational structure under the global Stallergenes Greer umbrella, ensure Stallergenes’s commitment to remaining customer-centric and help strengthen Stallergenes’s culture dedicated to innovation and excellence in execution. He served as Managing Director of UCB France and Executive Vice President of Ucb France at Ucb S.A. since December 30, 2011. He served as Executive Vice President of Technical Operations, QA & HSE at UCB SA since June 2008. He served as Head of Technical Operations and Quality team at Ucb S.A. From 1985 to 1992, Mr. Antonelli served at Enichem, in Italy, as Research Fellow and then Head of the Molecular and Cell Biology Unit. In 1992, he joined Serono, where he served several senior Managerial positions, gathering about 20 years experience in the Quality Assurance and Biotech Manufacturing fields as Senior Vice President of Biotech Manufacturing Process Development of Merck Serono based in Geneva. Prior to joining UCB, he spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development. He has been the Chairman of Ucb Farchim Sa since December 2011. He holds a Degree in Plant Biology from the University of Bari, Italy and qualified the ENI’s Post-graduate Programme in Biotechnology and in Advanced Genetics (Molecular and Somatic cell Genetics) at the Catholic University of Piacenza and the Iowa State University of Ames, USA.

CEO Compensation
  • Insufficient data for Michele to compare compensation growth.
  • Insufficient data for Michele to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure of the Stallergenes Greer management team in years:

1
Average Tenure
  • The average tenure for the Stallergenes Greer management team is less than 2 years, this suggests a new team.
Management Team

Fereydoun Firouz

TITLE
Executive Officer
COMPENSATION
€2M
AGE
54
TENURE
0.3 yrs

Michele Antonelli

TITLE
CEO & Director
AGE
58
TENURE
0.3 yrs

Matthias Vogt

TITLE
Chief Financial Officer
TENURE
1.6 yrs

Youssef Abbas

TITLE
Head of Investor Relations

Andrew Suchoff

TITLE
Global Head of People Operations & Talent Development

Tibor Nemes

TITLE
Executive VP & Head of Americas
TENURE
1 yrs

Daniel Smith

TITLE
Global Head of Information Technology
TENURE
3.1 yrs

Jérôme Tilly

TITLE
Senior Vice President of People Operations – Europe & International

Amer Jaber

TITLE
Executive Vice President of Operations - Europe

Petr Tor

TITLE
Head of Commercial Europe & International
Board of Directors Tenure

Average tenure and age of the Stallergenes Greer board of directors in years:

0.9
Average Tenure
58
Average Age
  • The average tenure for the Stallergenes Greer board of directors is less than 3 years, this suggests a new board.
Board of Directors

Stefan Meister

TITLE
Chairman of the Board
AGE
53
TENURE
0.3 yrs

Michele Antonelli

TITLE
CEO & Director
AGE
58
TENURE
0.4 yrs

Elmar Schnee

TITLE
Lead Independent Director
COMPENSATION
€130K
AGE
59
TENURE
0.8 yrs

Philip John Broadley

TITLE
Independent Director
COMPENSATION
€51K
AGE
57
TENURE
0.9 yrs

Jean-Luc Bélingard

TITLE
Independent Director
COMPENSATION
€75K
AGE
70
TENURE
2.9 yrs

Rodolfo Bogni

TITLE
Non-Executive Director
COMPENSATION
€60K
AGE
70
TENURE
3.8 yrs

Yvonne Schlaeppi

TITLE
Independent Non-Executive Director
COMPENSATION
€90K
AGE
58
TENURE
2.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Stallergenes Greer's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Stallergenes Greer has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AA6 News

Simply Wall St News

AA6 Company Info

Description

Stallergenes Greer plc, a biopharmaceutical company, engages in the development and commercialization of allergy immunotherapy products and services for diagnosis and treatment of allergies worldwide. The company offers sublingual products consisting of Staloral liquid sublingual drops placed under the tongue; Actair, a house dust mite tablet; and Oralair solid sublingual dissolving tablets placed under the tongue. It also provides a range of subcutaneous allergen extracts, including allergen extracts from the Greer Laboratories; Phostal, an allergen extract absorbed by calcium phosphate; Alustal allergen extract absorbed by aluminium hydroxide; and Alyostal venom and Albey used for the treatment of hymenoptera venom allergies. In addition, the company offers bulk extracts, sterile empty vials, and enzyme-linked immunosorbent assay components, as well as prescription services to veterinary dermatologists, reference laboratories, and distributors. Further, it provides skin testing devices by enabling the identification of allergens or allergens responsible for the allergy, sterile diluents and sterile empty vials, syringes, and other compendial products. The company was formerly known as Ares Allergy Holdings plc and changed its name to Stallergenes Greer plc in October 2015. Stallergenes Greer plc was incorporated in 2013 and is headquartered in London, the United Kingdom. Stallergenes Greer plc is a subsidiary of Ares Life Sciences I SARL.

Details
Name: Stallergenes Greer plc
AA6
Exchange: BST
Founded: 2013
€724,212,954
19,733,323
Website: http://www.stallergenesgreer.com
Address: Stallergenes Greer plc
Tower bridge House,
St Katharine’s Way,
London,
Greater London, E1W 1DD,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA STAGR Common Shares Euronext Paris FR EUR 08. Sep 2015
OTCPK STLL.F Common Shares Pink Sheets LLC US USD 08. Sep 2015
BST AA6 Common Shares Boerse-Stuttgart DE EUR 08. Sep 2015
LSE 0RB9 Common Shares London Stock Exchange GB EUR 08. Sep 2015
Number of employees
Current staff
Staff numbers
1,167
Stallergenes Greer employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/16 23:38
End of day share price update: 2019/05/13 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/21
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.